Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Krystal Biotech reported Q2 2026 revenue of $119.22M and diluted EPS of $1.79, reflecting 24.1% YoY growth driven by VYJUVEK sales expansion in the EU and Japan. Net income rose 42.9% to $54.77M. The company maintains ~95% gross margins through manufacturing optimizations. R&D pipeline advances include completed Phase 3 enrollment for KB803 and progress on other programs.
Krystal Biotech, Inc. reported second-quarter 2026 results with revenue of $119.22M and diluted EPS of $1.79, driven by continued VYJUVEK sales growth and expansion into new markets versus the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $119.22M | $96.04M | 24.1% |
| Net income² | $54.77M | $38.33M | 42.9% |
| Diluted EPS³ | $1.79 | $1.29 | 38.8% |
¹ Reported as “Product revenue, net”. ² Reported as “Net income”. ³ Reported as “Diluted income per common share”.
Business Highlights
- VYJUVEK net revenue for the quarter was $119.2M (YTD $235.6M), with growth driven by launches in the EU and Japan.
- Market expansion continued: product launched in the U.S. (2023), Germany (Aug 2025), France and Japan (Oct 2025); U.K. approved May 2026; pricing discussions are ongoing.
- High gross margins (approximately 95%) supported results; two in‑house commercial cGMP facilities and manufacturing optimizations reduced COGS per unit.
- R&D pipeline advancing: KB803 Phase 3 enrollment complete and programs KB801, KB407 and KB707 progressing, alongside multiple FDA designations.
Original SEC Filing: Krystal Biotech, Inc. [ KRYS ] - 10-Q - Aug. 03, 2026